Jasper Therapeutics
NASDAQ: JSPRRedwood City, US · Delaware corporation · 4 known investors
Find your way into Jasper Therapeutics
322 people in our graph share verified history with the Jasper Therapeutics team — schools, employers, funds. One of them is your warm intro.
Kate Wilschutzunlockedknows Jeet Mahal · together at Navigant Consulting (overlapped)
×6knows the team · via Johnson & Johnson
×3knows the team · via Illinois Institute of Technology
×2knows the team · via Navigant Consulting
Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases. The company is running clinical studies in chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma.
Founders & leadership
JS
Judith ShizuruFounder
HC
Herb CrossinChief Financial OfficerHerb Cross is Chief Financial Officer at Jasper Therapeutics, a biopharmaceutical company developing a monoclonal antibody candidate for mast cell-driven diseases. He has held CFO positions at multiple life sciences companies including Atreca, ARMO BioSciences, Balance Therapeutics, KaloBios Pharmaceuticals, and Affymax, and previously served as Vice President of Finance at Neoforma, PDL BioPharma, and Facet Biotech; he holds a BS in Business Administration from UC Berkeley and is a Certified Public Accountant.
JM
Jeet MahalinChief Executive OfficerJeet Mahal has over thirty years of experience in biotechnology and pharmaceutical development and commercialization, including operational roles at biotech startups and consulting engagements with major public firms. He holds an MBA, a Master's degree in Molecular Biology, and a Master's degree in Engineering, along with an undergraduate degree in Molecular Biology.
PC
Patrick CrutcherNamed on SEC filing
SL
Svetlana LucasNamed on SEC filing
WS
Wenru SongNamed on SEC filing
GF
Gregory F. KeenanNamed on SEC filing
Board
KV
TW
Thomas WiggansBoard director
ME
Matthew E. RosBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$132M disclosed across 1 round · 2026
▶$132MraisedAug 2026 · 40 investors · BiotechnologyRule 506(b)
▶$132MraisedAug 2026 · 40 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Herb CrossExecutive Officer
- Jeet MahalExecutive Officer, Director
- Patrick CrutcherDirector
- Thomas WiggansDirector
- Judith ShizuruDirector
- Svetlana LucasDirector
- Kurt von EmsterDirector
- Wenru SongExecutive Officer
- Gregory F. KeenanExecutive Officer
- Matthew E. RosDirector
- Offering amount
- $132M
- Amount sold
- $132M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
Seeking Alpha19 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Robinhood18 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
TradingView17 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Simply Wall St17 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Perplexity16 shared keywordsAn AI-powered answer engine providing accurate, trusted, and real-time answers to questions.
Companies competing with Jasper Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Jasper Therapeutics, Inc. (JSPR) stock: Climbs on Kira Merger and $132M Raise as Pipeline Consolidatesblockonomi.com · Aug 2026
Jasper Therapeutics (NASDAQ:JSPR): Why Is the Stock Back in Focus as the Latest Update Arrives?kalkinemedia.com · Aug 2026Frequently asked questions
- What does Jasper Therapeutics do?
- Jasper Therapeutics develops briquilimab, a targeted anti-KIT monoclonal antibody designed to deplete mast cells for treating chronic immunological and inflammatory diseases. The company is running clinical studies in chronic spontaneous urticaria, chronic inducible urticaria, and allergic asthma.
- Who founded Jasper Therapeutics?
- Jasper Therapeutics was founded by Judith Shizuru.
- Who are Jasper Therapeutics's investors?
- Jasper Therapeutics's investors include Avego BioScience Capital, TSVC, Abingworth, Ikarian Capital.
- How much funding has Jasper Therapeutics raised?
- Jasper Therapeutics has disclosed $132M raised across 1 round.
- Where is Jasper Therapeutics headquartered?
- Jasper Therapeutics is headquartered in Redwood City, US.